Closely held PolarityBio is developing investigational regenerative biologics for chronic wound healing, targeting some of the most refractory wounds in medicine. The company’s lead program and first entry into the...
Profound Medical (NASDAQ: PROF; TSX: PRN) has announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic...
Firefly Neuroscience (NASDAQ: AIFF) has announced advancements in research using resting EEG/cognitive EEG (ERP) brain scans, collected on its FDA 510(k)-cleared Evoke System, to potentially distinguish among the three...
MindMaze Therapeutics (SIX: MMTX) has announced the appointment of health tech veteran Zach Henderson as chief executive officer (CEO). With more than 30 years of experience scaling healthcare technology platforms and...
REGENXBIO (NASDAQ: RGNX) has announced new positive interim data from the Phase 1/2 AFFINITY DUCHENNE trial of RGX-202—a potential best-in-class therapy for Duchenne muscular dystrophy (DMD). Trial investigator Carolina...
Clearmind Medicine (NASDAQ: CMND) has announced the continuation of participant enrollment for the third cohort of its ongoing FDA-approved Phase 1/2a trial evaluating CMND-100, its proprietary non-hallucinogenic MEAI...
Spago Nanomedical (STO:SPAGO.ST; FRA:7UX.F) has announced that Torsten Malmström, PhD, has been appointed director of chemistry, manufacturing, and controls (CMC) and joins the company’s management team. Dr. Malmström...
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) has initiated a planned large-scale, longitudinal clinical study for CyPath Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer. The 2,000...
Tonix Pharmaceuticals (NASDAQ: TNXP) has announced that the American College of Clinical Pharmacology (ACCP) journal Clinical Pharmacology in Drug Development published results from clinical pharmacokinetic (PK) studies...
VolitionRx (NYSE American: VNRX) has announced the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test with closely held Fujifilm Vet Systems Co...